Author/Authors :
Sebastian de Bono، نويسنده , , Johann and Sandhu، نويسنده , , Shahneen and Attard، نويسنده , , Gerhardt، نويسنده ,
Abstract :
In this issue of Cancer Cell, Brenner et al. describe that the poly-(ADP) ribose polymerase (PARP) may mediate ERG function and that PARP blockade has antitumor activity in ETS gene-rearranged prostate cancer models. These data support the clinical evaluation of PARP inhibitors for treating ETS gene-rearranged prostate cancers.
